Authors

John L. Reagan, MD

Latest:

Serializer Test 2

Testing individual components

Beryl Manning-Geist, MD

Latest:

Dr Manning-Geist on Secondary Cytoreductive Surgery in Ovarian Cancer

Beryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.

Danielle M. Brander, MD, Duke Cancer Institute

Latest:

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

Kathryn Kline, MD, MPH

Latest:

Normalizing Motherhood in Medicine

Hematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.

Haifa Kathrin Al-Ali, MD

Latest:

Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in Myelofibrosis

Haifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.

Jennifer Sipos, MD, Ohio State University

Latest:

Treating BRAF V600 and NTRK Gene Fusion Positivity

Debu Tripathy, MD

Latest:

Dr Tripathy on the Treatment of HER2+ Breast Cancer

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

Steven Kaplan, MD

Latest:

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Saad Usmani, MD, MBA, FACP, FASCO

Latest:

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

Soo-Ryum Yang, MD

Latest:

Unmet Needs in LCNEC

Panelists discuss what they would like to see in future trials to address the unmet needs and challenges in treating patients diagnosed with lung large cell neuroendocrine carcinoma (LCNEC).

Ann M. Gillenwater, MD

Latest:

Dr Gillenwater on Phase 1 Data for ASP-1929 Plus Pembrolizumab in HNSCC

Ann M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Damon R. Reed, MD

Latest:

Dr Reed on Genetic Differences Between Ewing Sarcoma and Osteosarcoma

Damon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.

Yale Cancer Center

Latest:

Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy

Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.

Robert Rintoul, BSc, MB ChB, MRCP, PhD, FRCP

Latest:

Dr. Rintoul on the Importance of MRD Assessment in NSCLC

Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.

Katrina S. Pedersen, MD, MS

Latest:

Dr Pederson on Novel Therapies for the Management of Targetable mCRC

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Maher Albitar, MD

Latest:

Inside the Clinic: Experts Explore Case Studies in DLBCL

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Russ Conroy

Latest:

Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.

Suneel Kamath, MD

Latest:

Dr Kamath on the Rise in Incidence of Pancreatic Cancer

Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.

Nader Sanai, MD

Latest:

Dr Sanai on the Evaluation of BDTX-1535 in EGFR-Mutated High-Grade Glioblastoma

Nader Sanai, MD, discusses a phase 1 trial investigating BDTX-1535 in patients with recurrent, EGFR-mutated high-grade glioblastoma.

Florida Cancer Specialists & Research Institute

Latest:

Breaking New Ground in Biological Therapies for Cancer

The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.